U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Drug Trials Snapshots: RYZNEUTA
  1. Drug Approvals and Databases

Drug Trials Snapshots: RYZNEUTA

HOW TO USE THIS SNAPSHOT

The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.

LIMITATIONS OF THIS SNAPSHOT:

Do not rely on Snapshots to make decisions regarding medical care. Always speak to your healthcare provider about the benefits and risks of a drug.

Some of the information in this Snapshot is for presentation purposes and does not represent the approved conditions of use of this drug. Refer to the RYZNEUTA Prescribing Information for all the approved conditions of use of this drug (e.g., indication(s), population(s), dosing regimen(s), safety information).

Snapshots are limited to the information available at the time of the original approval of the drug and do not provide information on who participated in clinical trials that supported later approvals for additional uses of the drug (if applicable).

RYZNEUTA (efbemalenograstim alfa)
rīz-new-ta
Evive Biotechnology
Approval date: November 16, 2023


DRUG TRIALS SNAPSHOT SUMMARY:

What is the drug for?

RYZNEUTA is a prescription drug that is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

How is this drug used?

ARYZNEUTA is a subcutaneous injection that is taken once approximately 24 hours after cytotoxic chemotherapy.

Who participated in the clinical trials?

The FDA approved RYZNEUTA based on evidence from two main clinical trials, GC-627-04 and GC-627-05, in 515 patients with breast cancer receiving chemotherapy. The trials were conducted at 52 sites in 5 countries including Hungary, Russia, Ukraine, Bulgaria, and the United States.

There was one patient included in the trial from the United States, and 514 patients were included from sites outside of the United States.

The same trials (GC-627-04 and GC-627-05) were used to assess efficacy and safety.

How were the trials designed?

RYZNEUTA was evaluated in two main clinical trials that were randomized and controlled. A total of 515 patients were randomized to receive RYZNEUTA or placebo, or Neulasta, after receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia to treat metastatic breast cancer. Both trials evaluated the benefit and side effects of RYZNEUTA in patients.

The benefit of RYZNEUTA was based on the mean duration of severe neutropenia seen in patients after receiving either RYZNEUTA or control (placebo or Neulasta).


DEMOGRAPHICS SNAPSHOT:

Figure 1 summarizes how many participants by sex were enrolled in the clinical trials used to evaluate the efficacy of RYZNEUTA.

Figure 1. Baseline Demographics by Sex

Pie chart summarizing how many male and female patients were in the clinical trial. In total, 0 (0%) male patients and 515 (100%) female patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 2 summarizes the percentage of participants by race enrolled in the clinical trials used to evaluate the efficacy of RYZNEUTA.

Figure 2. Baseline Demographics by Race

Pie chart summarizing how many White and Black or African American patients were in the clinical trial. In total, 515 (99.8%) White patients and 1 (0.2%) Black or African American patient participated in the clinical trial.

Source: Adapted from FDA Review

Figure 3 summarizes the percentage of participants by age enrolled in the clinical trials used to evaluate the efficacy of RYZNEUTA.

Figure 3. Baseline Demographics by Age

Pie chart summarizing how many patients by age were in the clinical trial. In total, 444 (86%) patients between 18 and 65 years of age and 71 (14%) patients older than 65 years of age participated in the clinical trial.

Source: Adapted from FDA Review

Figure 4 summarizes the percentage of participants by ethnicity enrolled in the clinical trials used to evaluate the efficacy of RYZNEUTA.

Figure 4. Baseline Demographics by Ethnicity

Pie chart summarizing how many Hispanic and not Hispanic patients were in the clinical trial. In total, 3 (0.6%) Hispanic or Latino patients and 512 (99.4%) not Hispanic or Latino patients participated in the clinical trial.

Source: Adapted from FDA Review

What are the benefits of this drug?

The studies demonstrated that the mean duration of severe neutropenia in cycle 1 was lower for RYZNEUTA-treated patients as compared to placebo-treated patients, and the mean days of severe neutropenia of RYZNEUTA-treated patients did not exceed that of Neulasta-treated patients by more than 0.6 days (prespecified noninferiority margin) in cycle 1 of chemotherapy. RYZNEUTA was noninferior to Neulasta and more effective than placebo at decreasing the duration of severe neutropenia, which in patients receiving myelosuppressive chemotherapy can reduce complications associated with cancer treatment including hospitalization and life-threatening infection.

Were there any differences in how well the drug worked in clinical trials among sex, race, and age?

  • Sex: RYZNEUTA was only assessed in female patients. It is reasonable to believe that RYZNEUTA works as well in male patients as it does in female patients due to phase 1 studies done in healthy male volunteers.
  • Race: Although the clinical trials contained one Black patient, it is reasonable to believe that RYZNEUTA works as well in Black patients as well as it does in White patients because how U.S.-licensed granulocyte colony stimulating factors work have not been shown to be dependent on race in patients.
  • Age: RYZNEUTA worked similarly in patients younger and older than 65 years of age.

What are the possible side effects?

RYZNEUTA can cause fatal splenic rupture, acute respiratory distress syndrome, serious allergic reactions including anaphylaxis, sickle cell crises in patients with sickle cell disorders, glomerulonephritis, thrombocytopenia, capillary leak syndrome, and myelodysplastic syndrome and acute myeloid leukemia in patients with breast and lung cancer.

The most common side effects of RYZNEUTA are nausea, anemia, and thrombocytopenia.

Were there any differences in side effects among sex, race, and age?

  • Sex: There were no males included in the main trials, therefore, the difference in side effects among males and females cannot be assessed.
  • Race: The occurrence of side effects in race could not be determined because the number of patients of races other than White was small.
  • Age: The occurrence of side effects was similar in patients younger and older than 65 years of age.

GLOSSARY

CLINICAL TRIAL: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.
COMPARATOR: A previously available treatment or placebo used in clinical trials that is compared to the actual drug being tested.
EFFICACY: How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.
PLACEBO: An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.
SUBGROUP: A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.

PRESCRIBING INFORMATION

Back to Drug Trials Snapshots

 

Back to Top